Develops treatments for acute and chronic pain management.
Trevena, Inc. is a dynamic biopharmaceutical firm specializing in the development and commercialization of innovative therapies tailored for patients grappling with central nervous system disorders. Central to its portfolio are cutting-edge product candidates such as OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand designed to effectively manage moderate-to-severe acute pain. Additionally, Trevena is advancing TRV027, targeting acute lung injury associated with conditions like acute respiratory distress syndrome and abnormal blood clotting in COVID-19 patients. Other promising candidates include TRV250, a G protein biased delta-opioid receptor agonist for acute migraine, TRV734 for moderate-to-severe acute and chronic pain, and TRV045, a novel S1P modulator for chronic pain management.
Founded in 2007 and headquartered in Chesterbrook, Pennsylvania, Trevena, Inc. collaborates closely with esteemed institutions like Imperial College London to advance its research initiatives, particularly in evaluating TRV027's potential in COVID-19 patients. The company's strategic focus on innovative treatments underscores its commitment to addressing critical medical needs and enhancing patient outcomes. By leveraging pioneering research and development approaches, Trevena aims to redefine therapeutic standards and positively impact the lives of individuals worldwide.
Through its dedication to scientific excellence and strategic partnerships, Trevena continues to expand its footprint in the biopharmaceutical industry. With a robust pipeline and a mission-driven approach, the company remains at the forefront of advancing treatments for central nervous system disorders, offering hope and new possibilities for patients and healthcare providers alike.